247 related articles for article (PubMed ID: 33002672)
1. Cost-Utility of Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Lin J; Gibbons A; Smiddy WE
Ophthalmol Retina; 2021 Jul; 5(7):656-663. PubMed ID: 33002672
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
3. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
5. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Yannuzzi NA; Smiddy WE
Ophthalmology; 2018 Sep; 125(9):1393-1400. PubMed ID: 29606379
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.
Khan M; Wai KM; Silva FQ; Srivastava S; Ehlers JP; Rachitskaya A; Babiuch A; Deasy R; Kaiser PK; Schachat AP; Yuan A; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2017 Jun; 48(6):465-472. PubMed ID: 28613352
[TBL] [Abstract][Full Text] [Related]
7. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
Pennington B; Alshreef A; Flight L; Metry A; Poku E; Hykin P; Sivaprasad S; Prevost AT; Vasconcelos JC; Murphy C; Kelly J; Yang Y; Lotery A; Williams M; Brazier J
Pharmacoeconomics; 2021 Aug; 39(8):913-927. PubMed ID: 33900585
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
10. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P
JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
12. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
17. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
[TBL] [Abstract][Full Text] [Related]
18. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]